Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan 8;39(2):197-201.
doi: 10.1016/j.vaccine.2020.11.054. Epub 2020 Nov 24.

New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates

Takehiro Ura  1 , Akio Yamashita  2 , Nobuhisa Mizuki  1 , Kenji Okuda  3 , Masaru Shimada  4
Affiliations
Review

New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates

Takehiro Ura et al. Vaccine. .

Abstract

The threat of the current coronavirus disease pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is accelerating the development of potential vaccines. Candidate vaccines have been generated using existing technologies that have been applied for developing vaccines against other infectious diseases. Two new types of platforms, mRNA- and viral vector-based vaccines, have been gaining attention owing to the rapid advancement in their methodologies. In clinical trials, setting appropriate immunological endpoints plays a key role in evaluating the efficacy and safety of candidate vaccines. Updated information about immunological features from individuals who have or have not been exposed to SARS-CoV-2 continues to guide effective vaccine development strategies. This review highlights key strategies for generating candidate SARS-CoV-2 vaccines and considerations for vaccine development and clinical trials.

Keywords: SARS-CoV-2; Vaccine; Vector.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Wertheim J.O., Chu D.K., Peiris J.S., Kosakovsky Pond S.L., Poon L.L. A case for the ancient origin of coronaviruses. J Virol. 2013;87:7039–7045. - PMC - PubMed
    1. Grifoni A., Weiskopf D., Ramirez S.I., Mateus J., Dan J.M., Moderbacher C.R. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell. 2020;181(1489–501) - PMC - PubMed
    1. Woo P.C., Huang Y., Lau S.K., Yuen K.Y. Coronavirus genomics and bioinformatics analysis. Viruses. 2010;2:1804–1820. - PMC - PubMed
    1. Ou X., Liu Y., Lei X., Li P., Mi D., Ren L. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020;11:1620. - PMC - PubMed
    1. Walls A.C., Park Y.J., Tortorici M.A., Wall A., McGuire A.T., Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020;181(281–92) - PMC - PubMed

Publication types

MeSH terms